Inhibition of human platelet aggregation by amides and ester of salicylic acid with platelet-activating factor analogs.
The influence of acetyl salicylic acid (ASA) derivatives with platelet-activating factor (PAF) lipid analogs on PAF-induced human platelet aggregation has been studied. It was found that the ASA amide with an ethanolamine plasmalogen PAF analog (1-0-alk-1'-enyl-2-acetyl-sn-glycero-3-phospho-(N-2'-acetoxybenzoyl)ethanolamine) and the ASA ester with a choline plasmalogen PAF analog (1-0-alk-1'-enyl-2-(2'-acetoxybenzoyl)-sn-glycero-3-phosphocholine) at concentrations of 10-7-10-6 M effectively inhibit PAF-induced aggregation of human platelets. In contrast to these compounds, the ASA amide with an alkyl PAF analog (1-0-alkyl-2-acetyl-sn-glycero-3-phospho-(N-2'-acetoxybenzoyl)ethanolamine) did not inhibit PAF-induced platelet aggregation. As possible mechanisms of action of the studied compounds, the blockade of PAF-receptor and cyclooxygenase inhibition are proposed.
Kulikov
V I
VI
Research and Development Center for Medical Biotechnology, Ministry of Public Health of the Russian Federation, Moscow, 123182, Russia.
Muzya
G I
GI
D000577:Amides / Q000737:chemistry; D000890:Anti-Infective Agents / Q000737:chemistry / Q000494:pharmacology; D004952:Esters / Q000737:chemistry; D006801:Humans; D015394:Molecular Structure; D010972:Platelet Activating Factor / Q000031:analogs & derivatives* / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D020156:Salicylic Acid / Q000737:chemistry / Q000494:pharmacology*
D000577:Amides; D000890:Anti-Infective Agents; D004952:Esters; D010972:Platelet Activating Factor; D020156:Salicylic Acid